Edmond DE Rothschild Holding S.A. lowered its stake in Baxter International Inc. (NYSE:BAX – Free Report) by 10.4% during the third quarter, Holdings Channel.com reports. The fund owned 2,183,278 shares of the medical instruments supplier’s stock after selling 253,774 shares during the quarter. Edmond DE Rothschild Holding S.A.’s holdings in Baxter International were worth $52,399,000 at the end of the most recent reporting period.
Other large investors also recently added to or reduced their stakes in the company. CX Institutional increased its stake in shares of Baxter International by 2.3% during the third quarter. CX Institutional now owns 19,858 shares of the medical instruments supplier’s stock worth $477,000 after purchasing an additional 448 shares in the last quarter. Silver Grove Financial Group Inc. raised its position in shares of Baxter International by 28.8% during the 3rd quarter. Silver Grove Financial Group Inc. now owns 2,031 shares of the medical instruments supplier’s stock worth $49,000 after purchasing an additional 454 shares during the last quarter. Baird Financial Group Inc. lifted its stake in Baxter International by 1.1% in the 2nd quarter. Baird Financial Group Inc. now owns 44,722 shares of the medical instruments supplier’s stock valued at $953,000 after buying an additional 476 shares in the last quarter. Global Retirement Partners LLC lifted its stake in Baxter International by 45.8% in the 3rd quarter. Global Retirement Partners LLC now owns 1,566 shares of the medical instruments supplier’s stock valued at $38,000 after buying an additional 492 shares in the last quarter. Finally, North Dakota State Investment Board boosted its holdings in Baxter International by 3.3% in the 3rd quarter. North Dakota State Investment Board now owns 15,735 shares of the medical instruments supplier’s stock worth $378,000 after buying an additional 500 shares during the last quarter. 90.19% of the stock is currently owned by institutional investors and hedge funds.
Baxter International Trading Down 3.0%
Shares of Baxter International stock opened at $25.38 on Friday. The company has a debt-to-equity ratio of 1.20, a current ratio of 1.79 and a quick ratio of 1.19. The stock’s 50 day simple moving average is $24.61 and its 200-day simple moving average is $21.79. The stock has a market cap of $13.13 billion, a P/E ratio of -18.00, a P/E/G ratio of 3.84 and a beta of 0.68. Baxter International Inc. has a 1-year low of $15.73 and a 1-year high of $30.00.
Baxter International (NYSE:BAX – Get Free Report) last posted its quarterly earnings results on Thursday, October 29th. The medical instruments supplier reported $0.58 EPS for the quarter, beating the consensus estimate of $0.52 by $0.06. Baxter International had a positive return on equity of 16.23% and a negative net margin of 6.23%. The firm had revenue of $2.98 billion during the quarter, compared to analysts’ expectations of $2.91 billion. During the same quarter last year, the firm earned $0.69 earnings per share. The business’s revenue for the quarter was up 5.0% on a year-over-year basis. Analysts predict that Baxter International Inc. will post 2.10 EPS for the current fiscal year.
Baxter International Announces Dividend
The business also recently announced a quarterly dividend, which will be paid on Monday, January 4th. Shareholders of record on Friday, November 27th will be issued a $0.01 dividend. This represents a $0.04 annualized dividend and a yield of 0.2%. The ex-dividend date is Friday, November 27th. Baxter International’s dividend payout ratio is presently -2.84%.
Wall Street Analyst Weigh In
Several equities research analysts have commented on the company. Wolfe Research assumed coverage on Baxter International in a research note on Tuesday, October 20th. They set a “peer perform” rating for the company. Weiss Ratings upgraded Baxter International from a “sell (d-)” rating to a “sell (d)” rating in a research report on Friday, October 30th. JPMorgan Chase & Co. lowered their price target on Baxter International from $26.00 to $25.00 and set a “neutral” rating on the stock in a research note on Friday, October 30th. Citigroup dropped their price target on Baxter International from $28.00 to $27.00 and set a “neutral” rating for the company in a research report on Monday, October 5th. Finally, Jefferies Financial Group reissued a “hold” rating and issued a $25.00 price objective on shares of Baxter International in a research note on Thursday, October 29th. One research analyst has rated the stock with a Buy rating, ten have issued a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat, Baxter International currently has a consensus rating of “Reduce” and an average target price of $23.27.
Baxter International Company Profile
Baxter International is a global healthcare company that develops and supplies products used in hospitals, clinics and other care settings. Its offerings include intravenous solutions and administration sets, infusion pumps, medication-delivery systems, and products for surgical and hospital care. The company also provides patient-monitoring and connected-care technologies, including products associated with Hillrom, which Baxter acquired in 2021. Its products and services support healthcare professionals and patients in countries around the world.
Featured Articles
- Five stocks we like better than Baxter International
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Want to see what other hedge funds are holding BAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Baxter International Inc. (NYSE:BAX – Free Report).
Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.
